159 related articles for article (PubMed ID: 18570663)
1. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.
Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2007 Apr; 20(4):416-26. PubMed ID: 17384650
[TBL] [Abstract][Full Text] [Related]
4. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
5. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
[TBL] [Abstract][Full Text] [Related]
7. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant irradiation for axillary metastases from malignant melanoma.
Ballo MT; Strom EA; Zagars GK; Bedikian AY; Prieto VG; Mansfield PF; Lee JE; Gershenwald JE; Ross MI
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):964-72. PubMed ID: 11958890
[TBL] [Abstract][Full Text] [Related]
9. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.
Spanknebel K; Coit DG; Bieligk SC; Gonen M; Rosai J; Klimstra DS
Am J Surg Pathol; 2005 Mar; 29(3):305-17. PubMed ID: 15725798
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
[TBL] [Abstract][Full Text] [Related]
12. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative.
Murali R; DeSilva C; McCarthy SW; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Apr; 19(4):1089-99. PubMed ID: 22271204
[TBL] [Abstract][Full Text] [Related]
14. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
15. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases.
Holtkamp LH; Wang S; Wilmott JS; Madore J; Vilain R; Thompson JF; Nieweg OE; Scolyer RA
Ann Surg Oncol; 2015 Sep; 22(9):2972-7. PubMed ID: 25990968
[TBL] [Abstract][Full Text] [Related]
16. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
17. Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.
Kaufman KL; Mactier S; Armstrong NJ; Mallawaaratchy D; Byrne SN; Haydu LE; Jakrot V; Thompson JF; Mann GJ; Scolyer RA; Christopherson RI
Clin Exp Metastasis; 2014 Apr; 31(4):407-21. PubMed ID: 24435119
[TBL] [Abstract][Full Text] [Related]
18. ZNF23 Suppresses Cutaneous Melanoma Cell Malignancy via Mitochondria-Dependent Pathway.
Zhang X; Ding C; Tian H; Dong X; Meng X; Zhu W; Liu B; Wang L; Huang M; Li C
Cell Physiol Biochem; 2017; 43(1):147-157. PubMed ID: 28848158
[TBL] [Abstract][Full Text] [Related]
19. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Heino J; Pyrhönen S
Melanoma Res; 2004 Feb; 14(1):29-37. PubMed ID: 15091191
[TBL] [Abstract][Full Text] [Related]
20. Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma.
Tas F; Erturk K
Ann Plast Surg; 2019 Oct; 83(4):455-458. PubMed ID: 31524742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
